Galcanezumab for the Prevention of Migraine

Abstract

Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.

Keywords::

• CGRP monoclonal antibody
• galcanezumab
• headache
• migraine
• prevention
• treatment

Financial & competing interests disclosure

DI Friedman serves on advisory boards for Allergan, Amgen, Biohaven Pharmaceuticals, electroCore, Eli Lilly, Impel, Invex Therapeutics, Lundbeck, Revance, Satsuma, Supernus, Teva, Theranica and Zosano. The author received research grant support from Allergan, Eli Lilly, Merck and Zosano. She received compensation as a contributing author for MedLink Neurology and Medscape and as an editorial board member of Neurology Reviews. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.